Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Expeditors International of Wshngtn Inc (EXPD) vs Smith & Nephew plc (SNN) Price & Performance

Expeditors International of Wshngtn IncTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Expeditors International of Wshngtn Inc vs Smith & Nephew plc — how do they compare? Expeditors International of Wshngtn Inc trades at $181.24 (market cap $23.24B), while Smith & Nephew plc trades at $31.44 (market cap $12.81B). The key difference: Expeditors International of Wshngtn Inc is the larger of the two by market cap, and Smith & Nephew plc pays the higher dividend (2.54%). Which is the better fit depends on your goals.

EXPDSNN
Market Cap
$23.24B$12.81B
Sector
IndustrialsHealth
52-Week High
$178.22$38.70
52-Week Low
$111.37$28.73
Enterprise Value
$22.49B$15.58B
Dividend Yield
0.91%2.54%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Expeditors International of Wshngtn Inc

EXPD trades at $180.87, up 1.49% with strong technical momentum and bullish moving averages. The company demonstrates solid fundamentals with consistent earnings beats, posting Q1 2026 EPS of $1.71 versus $1.33 expected. Revenue grew to $11.07B in 2025 with a 7.48% net margin and impressive 36.59% ROE. Recent dividend of $0.81 reinforces shareholder returns while cash flow trends show operational strength.

Despite trading above the $161.50 consensus target, EXPD's earnings momentum and operational efficiency support continued upside potential. Key risks include analyst skepticism with only 12% buy ratings and overbought technical conditions. The stock's premium valuation requires sustained execution amid transportation industry challenges and economic uncertainties.

Smith & Nephew plc

Smith & Nephew (SNN) trades at $31.41, up 5.28% today, with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growth from $5.8B in 2024 to $6.2B projected for 2025 and net income margin expanding to 10.14%. Recent product launches in robotics and wound care, plus a $500M share buyback, highlight strategic execution. Analyst consensus is mixed with 27% buy ratings but 68% hold, reflecting cautious optimism amid earnings volatility where two of the last four quarters missed expectations.

Outlook: SNN's recovery trajectory and product innovation support long-term growth, but investor patience is needed due to earnings inconsistency and moderate debt levels. Key risks include competitive pressures in medtech and execution on guidance. The stock presents a value opportunity if operational improvements continue, trading at reasonable valuations (P/E 21.5, P/S 2.18) versus sector peers.

Returns comparison

Trailing returns across standard periods

About Expeditors International of Wshngtn Inc

Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.

Read more on EXPD

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN